Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients
Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S215226502604005X?dgcid=rss_sd_all
Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S215226502604005X?dgcid=rss_sd_all
“Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article41267,
title = {Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S215226502604005X?dgcid=rss_sd_all}
}